Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.
Level 3 - non-randomized controlled study
Observational database cohort study
PubMed 37796527 · doi:10.1001/jama.2023.19574
What was done
A database study examined the association between glucagon-like peptide-1 (GLP-1) receptor agonists (such as semaglutide and liraglutide) used for weight loss and reports of gastrointestinal adverse events.
What was found
The abstract provides no numerical data, effect sizes, or specific findings.
Why it matters
Understanding the gastrointestinal safety profile of GLP-1 receptor agonists is critical given their widespread adoption for weight loss.
Limits
The abstract provides no sample size, comparator group details, specific adverse event categories, or numerical estimates. As an observational database study, it is also subject to residual confounding and potential reporting biases.
Cited by
- supports A 2023 JAMA study on GLP-1 adverse effects reported only 2 cases of pancreatitis among over 600 semaglutide users.